DBV Technologies

Biotech

DBV peanut allergy patch hits endpoint in phase 3 infant study

DBV chalked up a win for its beleaguered peanut allergy patch candidate, hitting the primary endpoint in a phase 3 clinical trial in infants.
Nick Paul Taylor Jun 8, 2022 8:40am

DBV preps 200 layoffs after nasty FDA reaction to peanut patch

Jan 7, 2021 11:18am

FDA turns back DBV Technologies' peanut allergy patch for kids

Aug 4, 2020 12:28pm

FDA chief Scott Gottlieb steps down—Chutes & Ladders

Mar 8, 2019 9:00am

DBV loses regulatory, R&D execs ahead of peanut drug refile

Mar 6, 2019 9:46am

DBV CMO leaves as peanut allergy player rejigs team

Jan 3, 2019 9:50am